Decreased IL-10 expression in stefin B-deficient macrophages is regulated by the MAP kinase and STAT-3 signaling pathways  by Maher, Katarina et al.
FEBS Letters 588 (2014) 720–726journal homepage: www.FEBSLetters .orgDecreased IL-10 expression in steﬁn B-deﬁcient macrophages
is regulated by the MAP kinase and STAT-3 signaling pathways0014-5793/$36.00  2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.febslet.2014.01.015
⇑ Corresponding author. Address: Department of Biochemistry, Molecular and
Structural Biology, Jozˇef Stefan Institute, Jamova 39, 1000 Ljubljana, Slovenia.
Fax: +386 1 477 3984.
E-mail address: natasa.kopitar@ijs.si (N. Kopitar-Jerala).Katarina Maher a,b, Janja Završnik a,b, Barbara Jericˇ-Kokelj a,b, Olga Vasiljeva a, Boris Turk a,c,d,
Nataša Kopitar-Jerala a,⇑
aDepartment of Biochemistry, Molecular and Structural Biology, Jozˇef Stefan Institute, Ljubljana SI-1000, Slovenia
b Jozˇef Stefan International Postgraduate School, Jamova 39, SI-1000 Ljubljana, Slovenia
cCentre of Excellence for Integrated Approaches in Chemistry and Biology of Proteins (CIPKeBiP), Jamova 39, SI-1000 Ljubljana, Slovenia
dDepartment of Chemistry and Biochemistry, Faculty of Chemistry and Chemical Technology, University of Ljubljana, Cesta v Mestni log 88A, SI-1000 Ljubljana, Slovenia
a r t i c l e i n f o a b s t r a c tArticle history:
Received 16 September 2013
Revised 7 January 2014
Accepted 8 January 2014
Available online 23 January 2014







Nitric oxideInnate immune responses are tightly regulated to avoid excessive activation and subsequent inﬂam-
matory damage to the host, and interleukin-10 (IL-10) plays a crucial role in preventing inﬂamma-
tion. Steﬁn B (cystatin B) is an endogenous inhibitor of cysteine proteinases. In steﬁn B-deﬁcient
bone marrow-derived macrophages (BMDMs), we detected an increase in the induction of the
LPS-induced pro-inﬂammatory signal nitric oxide (NO) but decreased IL-10 expression. The phos-
phorylation of ERK and p38 MAP-kinases was signiﬁcantly decreased in steﬁn B-deﬁcient macro-
phages, as was STAT-3 phosphorylation. These ﬁndings show that steﬁn B inﬂuences the
expression of anti-inﬂammatory IL-10 in response to the TLR4 agonist LPS.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The cystatins are endogenous, reversible and tight-binding
inhibitors of the papain (C1) and legumain (C13) families of the
cysteine proteases and have signiﬁcant similarities in the amino
acid sequence and in the protein structure [1,2]. Steﬁn B (cystatin
B) is an endogenous cysteine cathepsin inhibitor localized in the
cytosol and nucleus, where it interacts with histones and cathepsin
L [3]. A loss-of-function mutations in the steﬁn B gene are found in
patients with the Unverricht–Lundborg disease (EPM1), but its
physiological function in the pathogenesis of the disease is not
known [4,5]. Studies of steﬁn B-deﬁcient mice show that lack of
this inhibitor is associated with the signs of cerebellar granular cell
apoptosis, progressive ataxia and myoclonic seizures [6]. It was
demonstrated that steﬁn B deﬁciency sensitizes the cells to the oxi-
dative stress-induced cell death [7,8]. In the past, several studies
examined the inﬂuence of cystatins on nitric oxide (NO) and
cytokine synthesis, predominantly type II cystatins induce NO
secretion in IFN-c-primed mouse macrophages [9,10].IL-10 is a potent anti-inﬂammatory cytokine that is crucial for
dampening the inﬂammatory response after pathogen invasion
and acts to protect the host from excessive inﬂammation [11].
The anti-inﬂammatory function of IL-10 is demonstrated by the
phenotype of IL-10-deﬁcient mice that develop severe inﬂamma-
tory bowel disease due to the spontaneous chronic inﬂammation
[12,13]. During acute inﬂammation, IL-10 is primarily produced
by the macrophages and dendritic cells [14] and it functions to lim-
it the expression of pro-inﬂammatory cytokines and chemokines
[15]. The production of IL-10 in LPS-stimulated macrophages is
dependent on the signal transducer and activator of transcription
(STAT-3) transcription factor [16] and two mitogen-activated pro-
tein kinases (MAPK), extracellular signal-regulated kinase (ERK)
and p38 [17–19].
In this study we examined how does the lack of steﬁn B inﬂu-
ence NO synthesis and IL-10 expression in mouse primary macro-
phages. We detected increased NO production in steﬁn B-deﬁcient
BMDMs, whereas the down-regulation of IL-10 synthesis was due
to the signiﬁcantly decreased MAP kinase ERK and STAT-3 activa-
tion in steﬁn B-deﬁcient BMDMs. These results indicate that steﬁn
B is involved in immunomodulation and the signaling pathways
determined in steﬁn B-deﬁcient BMDMs could be important in
the pathology of EPM1.
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2.1. Reagents and cell culture
LPS from Escherichia coli (E. coli 055:B5, Sigma, St. Louis, USA)
was used at ﬁnal concentration of 100 ng/ml. Recombinant mouse
Interferon-c (IFN-c) (eBioscience, San Diego, CA, USA) was used at
a ﬁnal concentration of 100 U/ml. Antibodies used in Western blot-
ting were purchased from Abcam (Cambridge, UK). Anti-steﬁn B
(ab53725), anti-iNOS (ab3523), anti-ERK 1/2 (ab17942), anti-phos-
pho-STAT3 Y705 (ab76315), anti-STAT3 (ab50761), from Sigma (St.
Louis, USA) anti-diphosphorylated ERK 1/2 (M8159), from Cell Sig-
naling (Danvers, MA, USA) anti-phospho-p38 (9211) and anti-p38
(9212). Anti-cathepsin L antibodies were described in [20]. Recom-
binant mouse M-CSF was purchased from eBioscience (San Diego,
CA, USA) and used at a ﬁnal concentration of 40 ng/ml.
2.2. Mice
Steﬁn B (cystatin B)-deﬁcient mice were created as described
previously [6], provided by Dr. R.M. Myers, Stanford University
and bred in our local colony. Mice (8–12 weeks of age) used in this
study were wild type (WT) and steﬁn B-deﬁcient (KO), fully back-
crossed to FVB/N background. Steﬁn B heterozygous mice were
regularly intercrossed in order to prevent genetic drift. All mouse
studies were conducted in accordance with protocols approved
by the Veterinary Administration of the Republic of Slovenia
(VARS) and the government Ethical Committee. Procedures for ani-
mal care and use were in accordance with the ‘‘PHS Policy on Hu-
man Care and Use of Laboratory Animals’’ and the ‘‘Guide for the
Care and Use of Laboratory Animals’’.
2.3. Preparation of macrophages
Mouse primary bone marrow-derived macrophages (BMDMs)
were obtained by ex vivo differentiation from mouse bone marrow
progenitors in the presence of M-CSF over 7 days, as previously de-
scribed [21]. Cells were kept in DMEM supplemented with 20% FBS,
1% penicillin/streptomycin, 2 mM L-glutamine and M-CSF.
2.4. Nitric oxide measurements
Nitric oxide (NO) release was determined by measuring nitrite
by the Griess reaction [22] in the BMDM supernatants. Cells were
cultured in 96-well plates, stimulated with LPS and IFN-c for
18 h or IFN-c-primed overnight, washed, and then stimulated with
LPS for 18 h. Supernatants were collected and mixed with Griess
solutions. The absorbance was measured at 545 nm on a micro-
plate reader (Tecan Inﬁnite, Männedorf, Switzerland).
2.5. Enzyme-linked immunosorbent assay (ELISA)
Cells were cultured in 96-well plates, stimulated with LPS and
IFN-c for 18 h or IFN-c-primed overnight, washed, and then stim-
ulated with LPS for 18 h. Murine IL-10 cytokine was measured by
ELISA (Abcam, ab108870) in cell culture supernatants after indi-
cated stimulations according to the manufacturer’s instructions.
The absorbance was read on a microplate reader (Tecan Inﬁnite,
Männedorf, Switzerland) at a wavelength of 450 nm. Sample con-
centrations were calculated from the standard curve.
2.6. Whole cell lysates preparation and Western blot analysis
Monolayer BMDMs at 80% conﬂuence were ﬁrst washed with
ice-cold PBS and then scraped into the Nonidet P-40 lysis buffer
(20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% NonidetP-40, 10% glycerol, 1 mM sodium orthovanadate, 10 mM NaF,
10 mM b-glycerophosphate), supplemented with the Complete
protease inhibitor coctail (Sigma) and the Phosphatase inhibitor
coctail (Sigma, St. Louis, USA). Cells were incubated on ice for
30 min. The lysates were then clariﬁed by centrifugation at
13000g for 10 min at 4 C, and the protein concentrations of
the cell lysates were measured using the Bradford reagent (Bio-
Rad). The lysates were subjected to electrophoresis on 12.5%
SDS–PAGE gels followed by Western blotting as described previ-
ously [8]. The proteins were visualized with ECL (GE Healthcare)
according to the manufacturer’s instructions.
2.7. Quantitative real-time PCR
Total RNA was isolated from the BMDMs after stimulation with
LPS using PureLink RNA mini kit (Ambion), followed by DNase
treatment using TURBO DNA-free kit (Ambion). cDNA was synthe-
sized from RNAwith Precision nanoScript Reverse Transcription kit
(Primerdesign Ltd) using random nanomer primers. The following
primers designed by Primerdesign Ltd were used for the real-time
quantitative PCR: IL-10 (Il10) sense: 50-CATACTGCTAACCGAC
TCCTTAAT-30 and anti-sense: 50-GGGCATCACTTCTACCAGGTA-30.
Real-time PCR reaction was run on Mx3005P system (Agilent,
Stratagene products) using the following thermal proﬁle: 95 C
for 10 min, followed by 40 cycles of 95 C for 15 s and 60 C for
1 min. Additionally, melting curve (55–95 C) was performed at
the end of each run. The mRNA expressions of target genes were
normalized to the expression of Gapdh and B2m. The mRNA expres-
sion of genes was calculated considering their real-time PCR efﬁ-
ciencies using REST (Relative Expression Software Tool) 2009 and
presented as a fold increase, relative to the unstimulated cells
(control). The mRNA expression levels of genes in control samples
were normalized to 1.0.
2.8. Confocal microscopy
BMDMs were seeded on cover slides, stimulated with IFN-c and
LPS and ﬁxed with 4% paraformaldehyde in PBS (pH 7.2) for 10 min
and permeabilized with 0.1% Triton X-100 for additional 5 min.
Cathepsin L was labeled with mouse anti-cathepsin L monoclonal
antibody N135 [20] and steﬁn B with rabbit anti-steﬁn B polyclonal
antibodies. Fluorescence microscopy was performed using Carl
Zeiss LSM 510 confocal microscope. Secondary antibodies conju-
gated with Alexa Fluor 488 or Alexa Fluor 546 and rhodamine were
excited with an argon (488 nm) or He/Ne (543 nm) laser and emis-
sion was ﬁltered using a narrow band LP 505–530 nm (green ﬂuo-
rescence) and 560 nm (red ﬂuorescence) ﬁlter, respectively. Carl
Zeiss LSM image software 3.0 (Correlation Plots) was used to
evaluate co-localization between the two labeled proteins (i.e.,
between red and green ﬂuorescence signals).
2.9. Statistical analysis
Average results are presented as the mean ± S.D. from the num-
ber of assays indicated. Statistical signiﬁcance of the results was
determined using unpaired Student’s t-test, assuming unequal
variances. ⁄P < 0.05, ⁄⁄P < 0.01.
3. Results
3.1. Steﬁn B is up-regulated in classically activated mouse
macrophages
Previously studies showed that the gene transcripts for steﬁn B
were signiﬁcantly up-regulated upon differentiation of monocytes
into the macrophages [23]. We determined increased steﬁn B
Fig. 1. Steﬁn B is up-regulated in activated macrophages. (A) Mouse primary macrophages were stimulated with LPS (100 ng/ml), IFN-c (100 U/ml) for 18 h and IFN-c primed
for 18 h prior to LPS challenge. Steﬁn B expression was determined by Western blotting of total cell lysates. The signals were quantiﬁed by densiometry analysis using ImageJ
program. The results represent the mean value of the fold increase ± S.D. relative to the normalized WT BMDM negative control of three independent experiments with 3
different biological samples. ⁄⁄P < 0.01. (B) Cells were left untreated or primed overnight with 100 U/ml IFN-c and treated with 100 ng/ml LPS for 18 h. After indicated
treatments, cells were stained with anti-cathepsin L antibodies (red), and anti-steﬁn B antibodies, ﬁxed and labeled with Alexa conjugated secondary antibodies, as described
in Section 2. Scale bar: 10 lm. (C) Cathepsin activity was measured after LPS (100 ng/ml), IFN-c (100 U/ml) and IFN-c priming followed by LPS stimulation in WT and Steﬁn B
KO BMDMs. Cell lysates were prepared and labeled with 20 lM DCG-04 active site directed probe for 1 h at 37 C. Probe-labeled cathepsins were visualized by streptavidin
afﬁnity blotting. Incubation of these cell lysates with the cysteine-protease inhibitor E-64 and temperature denaturation completely abolish cathepsin activity. The signals
were quantiﬁed by densiometry analysis using ImageJ program. The results represent the mean value of the fold increase ± S.D. relative to the normalizedWT BMDM negative
control of 3 independent experiments, 3 different biological samples. ⁄P < 0.05.
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(Fig. 1A). Although its expression was up-regulated in classically
activated BMDMs, we could not detect any co-localization with
the lysosomal cathepsin L (Fig. 1B). Studies by Rinne et al. showed
that the reduced steﬁn B inhibitory activity, due to reduced
expression in lymphoid cells of EPM1 patients, resulted in a
marked increase of general cathepsin activity [24]. In line with thatFig. 2. Steﬁn B-deﬁciency results in elevated NO production and iNOS expression in
BMDMs. (A) Nitric oxide (NO) release was determined by the Griess reaction in the
BMDM supernatants. Cells were cultured in 96-well plates, stimulated with IFN-c
(100 U/ml), LPS (100 ng/ml) for 18 h or primed with IFN-c (100 U/ml), overnight,
followed by LPS (100 ng/ml) stimulation for 18 h. The absorbance was measured at
545 nm. Data were obtained from three independent experiments performed in
triplicate, with 3 different biological samples, and the results are presented as
means ± S.D. ⁄P < 0.05, ⁄⁄P < 0.01. (B) Cells were left untreated or primed with IFN-c-
(100 U/ml and stimulated with LPS (100 U/ml). Whole cell lysates were separated
by SDS–PAGE and analysed by Western blots with iNOS speciﬁc antibodies. The
signals were quantiﬁed by densiometry analysis using ImageJ program. The results
represent the mean value of the fold increase ± S.D. relative to the normalized WT
BMDM negative control of 3 independent experiments, with 3 different biological
samples. ⁄⁄P < 0.01.study we determined increased overall cathepsin activity in un-
treated and activated steﬁn B-deﬁcient BMDMs compared to WT
(Fig. 1C). As expected, we observed no cathepsin activity in the
negative controls. The above data indicate that in the cytosol steﬁn
B may act as an emergency inhibitor by inhibiting the cathepsins
that are released from the lysosomes upon damage, or it could
have alternative functions in the cytosol [25].
3.2. Classically activated steﬁn B-deﬁcient BMDMs produce increased
levels of NO due to increased levels of inducible nitric oxide synthase
(iNOS) expression
Previous studies by Verdot et al. showed that the cystatins have
immune-modulatory functions, independent of cathepsin inhibi-
tion [9]. We investigated the effect of steﬁn B deﬁciency on NO
production in mouse BMDMs. In line with the ﬁnding that LPS is
a powerful synergistic agent of NO induction [26], we also deter-
mined up-regulation of the NO production in BMDMs when
primed with IFN-c and stimulated with LPS. Moreover, steﬁn
B-deﬁcient BMDMs secrete signiﬁcantly higher levels of NO
compared to WT BMDMs (Fig. 2A). In macrophages, the inducible
nitric oxide synthase (iNOS), is the enzyme responsible for the
NO production in the immune defense against pathogens. To
examine whether the increased levels of NO in steﬁn B-deﬁcient
BMDMs are resulting from an increased iNOS protein expression,
Western blot analysis was performed on the IFN-c-primed and
LPS-treated lysates. As shown in Fig. 2B, steﬁn B-deﬁcient BMDMs
have increased iNOS expression, when compared to WT BMDMs
(Fig. 2B). The increased production of NO suggests the pro-inﬂam-
matory phenotype of steﬁn B-deﬁcient mice.
3.3. Steﬁn B deﬁciency in BMDMs modulates LPS-induced IL-10
production
Previous studies indicated that cystatins induce pro- and anti-
inﬂammatory cytokines in macrophages [9,10]. First, we analysed
the expression of IL-10, a potent anti-inﬂammatory cytokine that
has pleiotropic effects in immune regulation and inﬂammation.
Notably, we have detected a signiﬁcantly lower relative IL-10
mRNA expression levels in LPS-stimulated steﬁn B-deﬁcient
BMDMs, when compared to WT (Fig. 3A). Next, the IL-10 protein
expression was evaluated in cell culture supernatants of steﬁn
B-deﬁcient and WT BMDMs stimulated with IFN-c and LPS. We
determined decreased IL-10 expression in cell culture supernatants
from steﬁn B-deﬁcient BMDMs compared to WT BMDMs (Fig. 3B),
the result correlates well with the lower relative IL-10 mRNA
expression levels detected in steﬁn B-deﬁcient BMDMs.
3.4. Decreased IL-10 expression is due to decreased MAPK ERK1/2 and
STAT-3 activation in steﬁn B-deﬁcient BMDMs
The expression of IL-10 in BMDMs is dependent on two mito-
gen-activated protein kinases (MAPK), extracellular signal-regu-
lated kinase (ERK) and p38, therefore we analyzed the activation
of ERK1/2 and p38. BMDMs were primed with IFN-c, stimulated
with LPS and then analyzed by Western blots. In steﬁn B-deﬁcient
BMDMs we detected signiﬁcantly decreased levels of phosphory-
lated ERK 1/2 in all samples, however, the phosphorylation of
p38 was signiﬁcantly lower only in LPS-stimulated steﬁn B-deﬁ-
cient BMDMs, when compared to WT BMDMs (Fig. 4A). In order
to further deﬁne the intracellular signaling pathways in steﬁn
B-deﬁcient BMDMs we analyzed the activation of STAT-3
transcription factor in cell lysates generated after IFN-c and LPS
stimulation. Decreased phosphorylation of STAT-3 at Tyrosine
705 was detected in steﬁn B-deﬁcient than in WT BMDMs
(Fig. 4B), in agreement with the decreased IL-10 expression.
Fig. 3. IL-10 gene and protein expression is down-regulated in steﬁn B-deﬁcient BMDMs. (A) BMDMs were stimulated with LPS (100 ng/ml) for 4 h and mRNA expression was
determined relative to unstimulated BMDMs. mRNA expression was normalised to the reference genes Gapdh and B2m and presented as a fold increase over control samples
(unstimulated BMDMs) that were normalised to 1. Data were obtained from three independent experiments performed in triplicate, with 3 different biological samples; and
the results are presented as means ± S.D. ⁄⁄P < 0.01. (B) Cells were cultured in 96-well plates, stimulated with LPS (100 ng/ml), IFN-c (100 U/ml) for 18 h or primed with IFN-c
(100 U/ml) overnight, followed by LPS (100 ng/ml) stimulation for 18 h. Murine IL-10 was measured in cell culture supernatants by ELISA, as described in Section 2. Data
shown are representative of at least three independent experiments, with 3 different biological samples.
Fig. 4. Decreased activation of ERK and p38 kinases and STAT-3 in IFN-c and LPS-activated steﬁn B-deﬁcient BMDMs. (A and B) BMDMs were treated with LPS (100 ng/ml),
IFN-c (100 U/ml) for 1 h, or primed with IFN-c (100 U/ml) for 1 h, and subsequently stimulated with LPS (100 ng/ml) for 1 h. Whole cell lysates were subjected to SDS–PAGE
followed by Western blotting. Proteins of interest were detected using phospho-speciﬁc Ab against ERK 1/2, p38 and STAT-3 (Tyr 705). Total ERK 1/2, p38 and STAT-3 were
detected as controls. The signals were quantiﬁed by densiometry analysis using ImageJ program. The results represent the mean value of the fold increase ± S.D. relative to the
normalized WT BMDM negative control of 3 independent experiments, with at least 3 different biological samples. ⁄P < 0.05.
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suggesting that the differences in the phosphorylation were due to
the activation and not protein expression.
4. Discussion
In the present study we examined the signaling pathways
leading to the increased NO and decreased IL-10 production in
steﬁn B-deﬁcient BMDMs. We demonstrated that down-regulation
of the IL-10 synthesis is due to the decreased activation of the MAP
kinases ERK 1/2, p38 and STAT-3 in steﬁn B-deﬁcient BMDMs.These data provide underlying molecular mechanisms for pro-
inﬂammatory phenotype reported previously in steﬁn B-deﬁcient
mice [6]. The mechanisms that we observed in steﬁn B-deﬁcient
BMDMs could be compared to the signaling events in macrophages
triggered by ﬁlarial cystatins, particularly AvCystatin [27] and to a
some extent to mouse cystatin C [28].
Early study showed that the addition of chicken cystatin to
IFN-c-primed mouse macrophages increased NO production,
TNF-a and IL-10 expression, independently of cystatin inhibitory
activity towards cathepsins [9]. In our present work we showed
that IFN-c and LPS-activated steﬁn B-deﬁcient BMDMs produced
Fig. 5. Proposed steﬁn B action upon LPS and IFN-c stimulation in BMDM. (1) Steﬁn B acts as a cytosolic emergency cathepsin inhibitor and prevents excessive proteolysis. (2)
Steﬁn B increased activation levels of ERK as we determined higher levels of phosphorylated ERK in WT BMDM in comparison to StB KO BMDM. We propose that steﬁn B
might act on MAP2K or upstream. (3) Steﬁn B was implicated in STAT-3 activation either by promoting its phosphorylation by JAK or by preventing its dephosphorylation.
Both signaling pathways lead to IL-10 gene expression, however, precise steﬁn B role remains elusive. MAP2K; mitogen-activated protein kinase kinase, MAPK; mitogen-
activated protein kinase, StB; steﬁn B.
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The result is comparable with the ﬁnding of Frendeus et al.,
showing that the IFN-c-stimulated macrophages from cystatin
C-deﬁcient mice produced higher levels of NO than WT control
macrophages [28].
We further showed that upon LPS stimulation steﬁn B-deﬁcient
BMDMs have signiﬁcantly lower relative IL-10 mRNA expression
than WT BMDMs, and as a consequence produced lower levels of
IL-10 protein. IL-10 expression has been studied by several groups,
(for a review see [16]). In macrophages, the promoter region of the
IL-10 gene contains binding sites for the transcription factors
STAT-3 and Sp1 transcription factor (SP1) [29,30]. The two tran-
scription factors are controlled by MAP kinases: ERK and p38
[31]. In our present work we determined decreased ERK phosphor-
ylation in steﬁn B-deﬁcient macrophages, as well as decreased
STAT-3 phosphorylation upon IFN-c and LPS stimulations. In con-
trast to our results, Frendeus et al. reported that macrophages lack-
ing the extracellular cystatin C expressed higher levels of IL-10
mRNA upon IFN-c stimulation [28], suggesting that the two cysta-
tins may regulate IL-10 synthesis differently. However, not only
the localization of cystatin C, but also the cystatin C expression
in the activated immune cells is different from that of steﬁn B.
The SAGE studies reported that LPS stimulations resulted in up-
regulation of steﬁn B expression in human monocytes, whereas
cystatin C expression was not affected [32].
Our results are in accordance with the recent report regarding
the role of nematode cystatins in the activation of macrophages
[10,27]. Klotz et al. demonstrated that ﬁlarial cystatin, AvCystatin
inﬂuenced the host macrophages by activation of ERK 1/2 and
p38, that further lead to the expression IL-10 [27]. In addition,
AvCystatin induced phosphorylation of the transcription factors
CREB and STAT-3 by phospho-ERK dependent pathway. Applica-
tion of AvCystatin strongly reduced colitis in the mouse model,by up-regulating IL-10 [33]. Previous studies demonstrated that
steﬁn B interacted with the STAT-1 in monocyte-derived and pla-
cental macrophages [34]. However, the recent study from the same
group was unable to conﬁrm the interaction of steﬁn B with STAT-
1 [35]. They showed that steﬁn B interacted with several different
proteins in HIV-1-infected macrophages, among others also two
proteins involved in JAK/STAT signaling pathway [35]. Since steﬁn
B inﬂuences the activation of STAT-1 [34] and STAT-3 (our results),
we propose that it likely interferes with signaling pathway up-
stream of STAT-1 and STAT-3. The precise mechanism by which
steﬁn B inﬂuences JAK/STAT signaling is yet to be determined.
The anti-inﬂammatory function of steﬁn B is demonstrated in
the pro-inﬂammatory phenotype of steﬁn B-deﬁcient mice, that
have increased expression of apoptosis and glial activation genes
[36]. IL-10 plays an essential role in mediating inﬂammatory pro-
cesses not only in the cells of immune system, but also in the brain
[37]. It was reported to increase the survival of cerebellar granule
cells by blocking caspase-3-like activity [38]. Therefore we propose
that the decreased IL-10 expression in steﬁn B-deﬁcient mice could
contribute to the increased apoptosis in the cerebellum in EPM1.
Collectively, our study demonstrates that steﬁn B-deﬁciency in
BMDMs leads to the decreased expression of the anti-inﬂamma-
tory cytokine IL-10 (Fig. 5) and into the increased pro-inﬂamma-
tory NO secretion. The data suggest that the pro- inﬂammatory
phenotype of steﬁn B-deﬁcient could be a consequence of de-
creased IL-10 expression.
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